Genetic Analysis operates in the medical technology sector. The company conducts research and development in the field of diagnostics, with the greatest focus on the human microbiome. The technology is based on the company's research platform and the IVD products are used, for example, for testing and analysis of bacteria and viruses. The largest operations are found in the Nordic market and the products are mainly resold to laboratories. The company is headquartered in Oslo, Norway.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Bio-Rad Luxembourg S.À.R.L. | 22,49 | 22,49 | 2024-12-31 |
| Avanza Bank AB | 10,32 | 10,32 | 2024-12-31 |
| Erik Skår Schumann | 6,65 | 6,65 | 2024-12-31 |
| Nordnet Bank AB | 4,98 | 4,98 | 2024-12-31 |
| Lucellum AS | 4,86 | 4,86 | 2024-12-31 |
| Ochrino AS | 4,16 | 4,16 | 2024-12-31 |
| S. Munkhaugen AS | 3,54 | 3,54 | 2024-12-31 |
| Molver AS | 2,93 | 2,93 | 2024-12-31 |
| Biohit Oyj | 2,88 | 2,88 | 2024-12-31 |
| Leif Jørgen Moger | 2,67 | 2,67 | 2024-12-31 |
2025-11-27 Delårsrapport 2025-Q3
2026-02-25 Bokslutskommuniké 2025
